Current Report Filing (8-k)
December 19 2016 - 8:55AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 15, 2016
OPIANT PHARMACEUTICALS, INC.
(
Exact name
of registrant as specified in its charter)
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number
|
|
(IRS Employer Identification No.)
|
401 Wilshire Blvd., 12th Floor,
Santa Monica, CA
|
|
90401
|
(Address of Principal Executive
Offices)
|
|
(Zip Cope)
|
(424) 252-4756
|
Registrant’s telephone number, including area code
|
(Former name or former address if changed since last report,)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01 Entry into a Material Definitive Agreement.
On December 15, 2016, Opiant Pharmaceuticals, Inc. (the “Company”)
entered into a new office license agreement (the “New Lease”) with Premier Office Centers, LLC (“Premier”)
for its headquarters located on the 12th Floor of 401 Wilshire Blvd., Santa Monica, CA 90401. The New Lease will be effective March
1, 2017, the date after which the term of the current lease with Premier expires. Pursuant to the terms of the New Lease, the Company
will pay $5,157.40 per month to Premier. The New Lease has an initial term of 12 months and shall automatically renew for successive
12 month periods unless terminated by the Company at least 60 days prior to the termination date. Premier may terminate the New
Lease for any reason upon 30 days’ notice to the Company.
The foregoing summary of the material terms of the New Lease
is qualified in its entirety by reference to the full text of the New Lease, which is attached hereto as Exhibit 10.1 and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit
No.
|
|
Description
of Exhibit
|
10.1
|
|
Office License Agreement Amendment, effective March 1, 2017, by and between Opiant Pharmaceuticals, Inc. and Premier Office Centers, LLC.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
Date: December 19, 2016
|
By:
|
/s/
Dr. Roger Crystal
|
|
|
Name: Dr. Roger Crystal
|
|
|
Title: President and Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024